Select Page
Clinique médicale l'Actuel's Journal Club

For 30 years, the Clinique médicale l’Actuel, under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.

The “ART” of giving complex patients the tools of adherence

with Dr. Jean-Paul Kerba and Dr. Bertrand Lebouché



  • The definition of a “complex patient”
  • The increased risk of non-adherence in HIV-infected patients who have concomitant illnesses
  • Tools available to measure the risk factors associated with non-adherence
  • How to encourage patients to become active partners in their treatment, to promote medication adherence and achieve undetectability

This activity is supported
by an educational grant from:

Bristol-Myers Squibb



HIV-infected complex patients medication adherence

Dr. Lebouché discusses adherence-related problems among “complex patients”, i.e. those infected with HIV who also have concomitant illnesses. Despite the availability of highly effective antiretroviral therapies, too many of these patients are still too far from “undetectability for all”, the ultimate goal established at the 2014 International AIDS Conference in Melbourne.

Dr. Lebouché points out the existence of proven evaluation tools that allow for early intervention with these patients, who generally have a certain vulnerability on the psychosocial level. These tools enable physicians and other health care professionals to better counsel patients on the importance of medication adherence and how to overcome the associated obstacles.

Jean-Paul Kerba, MD

Jean-Paul Kerba, MD


Clinique médicale l’Actuel
Montréal, Québec, Canada


Bertrand Lebouché MD, PhD

Bertrand Lebouché MD, PhD


Assistant professor
Family medicine
Chronic Viral Illness Service
McGill University Health Centre (MUHC)
Montréal, Québec, Canada


You must be logged in to view the complete program

ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Jean-Paul Kerba, MD has a financial interest/relationship or affiliation in the form of:
Speakers Bureau, Faculty, Peer Reviewer Advisory Committee/Board: BMS, ViiV, Abbvie, Gilead

Bertrand Lebouché MD, PhD has a financial interest/relationship or affiliation in the form of:
Industry funded research/investigator, Speakers Bureau, Faculty, Peer Reviewer Advisory Committee/Board : MSD
Speakers Bureau, Faculty, Peer Reviewer Advisory Committee/Board: Gilead, ViiV, BMS, Abbvie

Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.